On Tuesday,
Algernon Pharmaceuticals Inc. (
CSE: AGN,
OTCQB: AGNPF,
Forum) reported positive trending interim data for the Phase 2b part of the Company’s Phase 2b/3 clinical study of NP-120 (Ifenprodil) Ifenprodil for COVID-19.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, stated that this interim data has provided AGN with some positive trending information, the team still needs to evaluate the full definitive results and statistics to be presented with the final data set.
“We will be especially interested to see the numbers on the overall time spent on ventilation and rate to ventilation to be reported in the final data set.”
For the full news release, click
here:
The Vancouver, BC-based clinical stage pharmaceutical development and drug repurposing company recently announced that
the final patient has been enrolled in its multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. The aggregate total number of patients enrolled from all countries participating in the study stands at 168.
CEO Moreau commented:
“I want to thank to the entire AGN team, including all of our clinical trial investigators and their staff, for helping us reach the goal of 100% patient enrollment. Our next big step is to see how the preliminary data is trending and we remain hopeful it will show that Ifenprodil is reducing both the severity and duration of a COVID-19 infection. Even with the recent success of certain vaccines in clinical trials, medical doctors need to have effective therapeutic treatment options as well.”
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.